Issue 33

RISING TIDES: NORTH AMERICAN DRUG REGULATIONS AND THE IMPACT ON BIG PSYCHEDELIC BUSINESS

With a watchful eye on shifting regulatory landscapes throughout North America, how might investors or operators interpret proposed or enacted loosening of drug restrictions and the impact on psychedelic business?

This two-part series examines the commercial implications of regulatory frameworks and proposed changes in North America.

How can successful for-profit psychedelics organisations and investors support the change-making work of non-profits? What is the role of each in an increasingly competitive business ecosystem, where are the friction points and what does the ideal relationship look like?

Join us on 7 July for a highly anticipated discussion between atai Life Sciences’ founder, Christian Angermayer and Multidisciplinary Association for Psychedelic Studies (MAPS) founder, Rick Doblin at the PSYCH Investor Summit: Research and Development

In a US$100 billion industry set to disrupt modern healthcare, hear these important insights and more on the critical path forward from leaders on the frontlines. Secure your tickets and visit the event page for more information.

ATAI LIFE SCIENCES TARGETS US$2.3 BILLION VALUATION IN U.S. IPO

The Berlin-based company, famously backed by tech entreprenuer Peter Thiel, is looking to raise as much as US$214.3 million through a U.S. initial public offering, targeting a valuation of about US$2.3 billion.

READ MORE

DEMOCRATS INTRODUCE NEW BILL TO END THE WAR ON DRUGS

The Drug Policy Reform Act introduced this week seeks to end federal criminal penalties for drug possession, expunge criminal drug records and invest in evidence-based approaches to drug policy.

READ MORE

BUSINESS & INVESTMENT

Field Trip Health announces completion of studies for novel psychedelic compound.


Novamind launches ketamine-assisted psychotherapy programme for Utah and Colorado healthcare workers.


MYND Life Sciences files patent applications for psilocybin analogues targeting clinical depression.


Red Light Holland buys into virtual reality and grow-at-home mushroom companies.


PsyTech announces nearly US$4 million raise to fund development of psychedelic-assisted therapies.


Core One Labs nears completion of patent application for biosynthetic psilocybin production system.


PharmaTher files FDA request to develop potential next-generation psychedelic depression treatment.


HaluGen Life Sciences’ psychedelics genetic test kit now on sale in US.


Filament announces completion of first GMP batch of pharmaceutical-grade natural psilocybin extract.


Vancouver’s Delic Labs researching psilocybin as alternative therapy for mental health issues.


MindScape clinic among first to introduce virtual reality component to ketamine-assisted treatments.


Mindset and InterVivo Solutions announce availability of first data from psychedelics programme.


Entheon Biomedical announces agreement to acquire Lobo Genetics.


Beckley Psytech researching DMT compound that could make therapy short and effective.


Resurgent Biosciences announces planned expansion into psychedelics research and IP development.


MagicMed agrees to acquisition by cannabinoid-focused biotechnology company Enveric Biosciences.


XPhyto provides progress report on mescaline programme for psychedelic therapies.


Filament discovers psilocybin-containing fungus cultivar four times more potent than existing options.


American Journal of Psychiatry publishes psychedelics treatment guidance led by Braxia Scientific.


The emerging revival of psychedelics in neuroscience.


Optimi Health advised to proceed with psilocybin study by Health Canada.


Cybin chooses anxiety disorders as initial targets for proprietary psychedelic molecule.


Mydecine unveils artificial intelligence drug discovery program.


Bright Minds Biosciences announces application to list on Nasdaq.


Wake Network partners with research organisation for clinical trials in psilocybin therapies.


Creso Pharma and Red Light Holland merge to form The HighBrid Lab.

In today’s fast-moving psychedelics industry, brand awareness and thought leadership in front of a qualified audience are crucial for growing operators. Would your organisation benefit from connecting with a network of investors ready to deploy capital? Partnership opportunities for the upcoming PSYCH Investor Summit: Research & Development are still available. Enquire with our team to learn more.

RESEARCH & SCIENCE


Currently illegal psychedelic drugs show huge promise for mental health and headaches.


Research confirms process by which ketamine acts as an antidepressant.


Miami news team explores psychedelic ketamine therapy sessions.


Placebo effect is the problem at the heart of modern psychedelic clinical research.


Massachusetts researchers may clear path for psychedelic treatment of psychiatric patients.


How psychedelics interact with the human body beyond brain cells.


Mike Tyson says psychedelics would have helped with mental health during his career.


Beckley Foundation founder and director discusses her 55 years as psychedelics pioneer.


Exploring four psychedelic drug trials aiming to break new ground in mental health.


Research position is Canada’s first to focus on psychedelic drug therapy for mental health.


Non-profit TheraPsil advocating for healthcare professionals to undergo psilocybin-assisted therapy.

REGULATION & LEGISLATION


Will psychedelics become legal in California?


The push for legal psychedelic-assisted therapy in Canada.